ここから本文です
Yahoo!ファイナンス
投稿一覧に戻る

(株)ジーエヌアイグループ【2160】の掲示板 2021/05/19

29

yakushimaru♡ 2021年5月19日 07:07

Ubiquitin-Induced Targeted Protein Degradation

Optimizing PROTACs and Small Molecule Protein Degraders for Pursuing Undruggable Targets

May 18-19, 2021 | ALL TIMES EASTERN DAYLIGHT (UTC-04:00)
https://www.drugdiscoverychemistry.com/Ubiquitin-Protein-Degradation

10:30 am
TRKing Down an Old Oncogene in a New Era of Targeted Protein Degradation

Michael Plewe, PhD, Senior Vice President, Medicinal Chemistry, Cullgen Inc.
Our research focuses on leveraging our ubiquitin-mediated, small molecule-induced protein degradation technology (uSMITE) for the treatment of cancer and other diseases. I will present the discovery and evaluation of first-in-class potent and selective degraders of tropomyosin receptor kinases (TRK) that inhibited cell growth with low nanomolar IC50 values and demonstrated sustained tumor growth inhibition in xenografted tumor models using the oral administration route.

(株)ジーエヌアイグループ【2160】 Ubiquitin-Induced Targeted Protein Degradation Optimizing PROTACs and Small Molecule Protein Degraders for Pursuing Undruggable Targets May 18-19, 2021 | ALL TIMES EASTERN DAYLIGHT (UTC-04:00) https://www.drugdiscoverychemistry.com/Ubiquitin-Protein-Degradation 10:30 am TRKing Down an Old Oncogene in a New Era of Targeted Protein Degradation Michael Plewe, PhD, Senior Vice President, Medicinal Chemistry, Cullgen Inc. Our research focuses on leveraging our ubiquitin-mediated, small molecule-induced protein degradation technology (uSMITE) for the treatment of cancer and other diseases. I will present the discovery and evaluation of first-in-class potent and selective degraders of tropomyosin receptor kinases (TRK) that inhibited cell growth with low nanomolar IC50 values and demonstrated sustained tumor growth inhibition in xenografted tumor models using the oral administration route.

開く

投稿一覧に戻る